Successful treatment of refractory checkpoint inhibitor‐induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab

Successful treatment of refractory checkpoint inhibitor‐induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab

Abstract Immune checkpoint inhibitors have established in the treatment of malignant melanoma and have significantly improved prognosis in advanced tumour stages. As they interfere with immunoregulatory pathways by blocking checkpoints, nonspecific activation of the immune system can result in the d...

Full description

Bibliographic Details
Main Authors: Inga Hansen, Julian Kött, Silke Heidenreich, Francis A. Ayuk, Patricia Doll, Finn Abeck, Nina Booken, Christoffer Gebhardt, Stefan W. Schneider
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:JEADV Clinical Practice
Subjects:
checkpoint inhibitor
extracorporeal photopheresis
hepatitis
immune‐related adverse events
infliximab
ipilimumab
Online Access:https://doi.org/10.1002/jvc2.288

Internet

https://doi.org/10.1002/jvc2.288

Similar Items